The preclinical data, developed in collaboration with Loma Linda University and the Steno Institute, establishes a clear rationale for using mesenchymal stem cells to address the immunological imbalances that trigger fetal loss. Researchers compared NomiCell™ against other stem cell variants, reporting superior efficacy in maintaining pregnancy in the CBA/J x DBA/2 model. Dr. George Delgado, Chief Medical Officer at Aureum, noted that while the findings are preliminary, they provide a necessary foundation for moving the product into human clinical trials.
Aureum Therapeutics Reports Preclinical Success in Preventing Miscarriage
Aureum Therapeutics has released findings in the Journal of Translational Medicine showing that its NomiCell™ stem cell therapy successfully prevented recurrent miscarriages in a standard animal model. The study, led by CEO Famela Ramos, highlights a potential immunological breakthrough for patients lacking viable treatment options.
Beyond the scientific validation, the company is positioning its approach as an ethical alternative to therapies derived from fetal tissue. By utilizing adult stem cells, Aureum aims to align its reproductive health programs with life-affirming standards, a sentiment echoed by advisory board member Bishop Joseph Coffey. The company is now leveraging these results to advance its pipeline, which currently includes two clinical-stage oncology programs and two preclinical projects focused on pregnancy loss.
Comments (0)
No comments yet. Be the first!